For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST
Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!
Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:15 CEST
Hensoldt forges drone alliance! Nordex peaked? Over 10% dividend with RE Royalties
A dividend yield of over 10% currently makes RE Royalties shares an attractive buy. The Company finances renewable energy projects and will also participate in future earnings from these projects. With success, since 2020, the Company has grown by 38% p.a. and has paid dividends for 25 quarters. By comparison, Nordex is far from such continuity in growth. However, Nordex is currently riding a wave of growth. After a 100% increase in the share price, analysts see little potential for Nordex shares. Meanwhile, Hensoldt shares would likely have jumped after the latest announcement, as the sensor specialist is forging a new German drone alliance. Is now the time to buy?
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read
Commented by Fabian Lorenz on October 13th, 2025 | 07:30 CEST
Drone boom and multiplication: Following DroneShield, RENK, and Standard Lithium, NEO Battery Materials shares are taking off!
Missed out on the multiplication of shares such as DroneShield, RENK, and Standard Lithium? Investors can still get in early with NEO Battery Materials. The Company is benefiting from the drone boom and the raw materials conflict between the US and China. NEO Battery Materials has developed advanced battery technology. The first manufacturer of drone batteries has already placed an order. In the future, the Company also plans to offer complete batteries itself. To save time in commercialization, a factory has been leased. This will allow for rapidly increasing sales and profits. The tariff and raw materials conflict between the US and China is likely to give NEO an additional boost. When will the stock take off?
Read
Commented by Fabian Lorenz on October 13th, 2025 | 07:05 CEST
Winners in the tariff war: Almonty Industries, MP Materials, Bayer
Stock market turmoil on Friday: Donald Trump once again threatens to wield the tariff club. This came in response to China's announcement to tighten export controls on rare earths. Yet, there are also winners in the raw materials battle between the two superpowers. In recent months, the US government has invested in companies such as MP Materials, focusing so far on rare earths and lithium. Will tungsten be next? This critical metal has not been mined in the US for a long time, and Almonty would be the logical partner to change that. Notably, while US stocks lost ground, in some cases heavily, on Friday, Almonty shares recovered significantly from their intraday lows.
Read
Commented by Fabian Lorenz on October 10th, 2025 | 07:20 CEST
Bombshell at Plug Power! Things are getting "critical" at Standard Lithium and Graphano Energy! Donald Trump is shaking up commodity stocks!
Investors are currently rushing to buy stocks in the rare earths, tungsten, and lithium sectors. The driving force behind this is the US government, which is investing in companies involved in critical raw materials to secure independence from China. Could Graphano Energy be next in line for government participation? In any case, no battery can function without the critical mineral, graphite. Graphano Energy is attractively valued and holds projects in Canada. Standard Lithium is benefiting from the hype surrounding critical metals. After rising more than 60% in four weeks, has a correction now arrived? Plug Power is in the midst of one. This week, the stock fell by over 20%. A capital measure and the surprising departure of the CEO are causing uncertainty.
Read
Commented by Fabian Lorenz on October 9th, 2025 | 07:20 CEST
GOLD RUSH to USD 5,000? DEFENSE STOCKS set for a billion-dollar contract! Barrick Mining, Hensoldt and Kobo Resources!
While the US government shutdown drags on, the rush for tangible assets persists. The pace at which gold and silver prices are climbing is almost alarming. On the stock market, AI and defense remain key drivers. With surprising ease, the price of gold has broken through the USD 4,000 mark - could USD 5,000 be next? Barrick Mining is also continuing its rally, while those looking for undiscovered gems amid this hype should take a closer look at Kobo Resources. The junior explorer could soon become a potential takeover target. In the defense sector, the capital market is waiting for major orders. One such order could now come from the German government. Hensoldt stands among the likely beneficiaries.
Read
Commented by Fabian Lorenz on October 8th, 2025 | 07:15 CEST
More than 50% upside potential! Zalando, thyssenkrupp, and stock market newcomer Finexity!
What is happening at thyssenkrupp? After the marine division (TKMS) drove the share price up this year with its defense fantasies, the planned IPO now appears to be stalling. Meanwhile, the steel division is once again dominating the headlines. Finexity, on the other hand, has successfully made the leap onto the trading floor. The next step is to attract greater investor attention. Those who get in early could profit, as the Company's growth prospects are excellent. Recently, Finexity announced plans for international expansion, targeting one of the most dynamic real estate markets in the world. In contrast, Zalando is facing strikes. When will the stock react? According to analysts, it might not. Yet they still see up to 50% upside potential.
Read